Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$36.71

-0.17 (-0.46%)

17:39
11/22/16
11/22
17:39
11/22/16
17:39

Boxer Capital reports 6% passive stake in The Medicines Co.

MDCO The Medicines Co.
$36.71

-0.17 (-0.46%)

11/15/16
PIPR
11/15/16
NO CHANGE
Target $106
PIPR
Overweight
Alnylam selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using today's selloff in shares of Alnylam Pharmaceuticals (ALNY) as a buying opportunity. Alnylam's partner The Medicine's Company (MDCO) presented today positive interim safety and efficacy data from the Phase II ORION-1 study of inclisiran, but the stock is weak today on one fatal heart attack in the 500mg inclisiran arm unrelated to study drug, Tenthoff tells investors in a research note. The analyst was impressed by the drug's efficacy and reiterates an Overweight rating on Alnylam with a $106 price target. The stock is down 3% to $48.36 in afternoon trading.
11/16/16
LEER
11/16/16
NO CHANGE
Target $57
LEER
Outperform
The Medicines Co. price target raised to $57 from $50 at Leerink
Leerink analyst Joseph Schwartz raised his price target for The Medicines Co. to $57 from $50 following the Phase 2 ORION-1 data presentation at the American Heart Association meeting, and after the company provided an extensive walk-through of the safety findings in addition to encouraging efficacy and durability data. The analyst also raised his probability of success for inclisiran to 60% from 50%. He reiterates an Outperform rating on the shares.
11/16/16
RBCM
11/16/16
NO CHANGE
RBCM
The Medicines Co. price target raised to $52 from $45 at RBC Capital
RBC Capital analyst Adnan Butt raised his price target on The Medicines Company after it reported Phase 2 data on its inclisiran drug that he views positively. The analyst says that the drug has differentiated efficacy and safety in LDL-C reduction. He thinks that safety questions created an overhang on the stock, but he still believes that the shares should have risen. The analyst believes that additional data due to be released by the company at the end of the year will be positive. He keeps an Outperform rating on the shares.
11/16/16
NEED
11/16/16
NO CHANGE
Target $98
NEED
Buy
Alnylam price target lowered to $98 from $137 at Needham
Needham analyst Alan Carr lowered his price target for Alnylam (ALNY) to $98 from $137 after the company announced that collaborator Sanofi (SNY) exercised its option to co-develop and co-commercialize fitusiran, with the analyst adjusting his models to reflect Sanofi taking greater share of revenue. He also notes that Alnylam's collaborator The Medicines Co. (MDCO) announced positive Phase 2 PCSK9 results. Carr reiterates a Buy rating on Alnylam's shares.

TODAY'S FREE FLY STORIES

ACN

Accenture

$121.23

0.51 (0.42%)

15:17
02/20/17
02/20
15:17
02/20/17
15:17
Hot Stocks
Accenture announces intent to acquire SinnerSchrader »

Accenture announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGG

CGG SA

15:13
02/20/17
02/20
15:13
02/20/17
15:13
Hot Stocks
CGG SA says secures consent from debt holders »

CGG SA CGG announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$31.17

-4.19 (-11.85%)

15:05
02/20/17
02/20
15:05
02/20/17
15:05
Hot Stocks
Impinj announces partnership, platform integration with STANLEY Healthcare »

Impinj announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

HRS

Harris

$109.46

0.81 (0.75%)

15:03
02/20/17
02/20
15:03
02/20/17
15:03
Hot Stocks
Harris wins $189M contract with UAE military »

Harris has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$100.52

-0.3 (-0.30%)

15:01
02/20/17
02/20
15:01
02/20/17
15:01
Hot Stocks
Alibaba announces strategic partnership with Bailian Group »

Alibaba and Chinese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 19

    Mar

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

, VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

14:58
02/20/17
02/20
14:58
02/20/17
14:58
Hot Stocks
Sierra Wireless says connected car products selected by Volkswagen »

Sierra Wireless (SWIR)…

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$10.62

0.08 (0.76%)

, CLMS

Calamos

$8.24

-0.03 (-0.36%)

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Progenics to replace Calamos in S&P 600 as of 2/20 close »

Calamos Asset Management…

PGNX

Progenics

$10.62

0.08 (0.76%)

CLMS

Calamos

$8.24

-0.03 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 01

    Mar

SFLY

Shutterfly

$48.06

0.66 (1.39%)

, VASC

Vascular Solutions

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Shutterfly to replace Vascular Solutions in S&P 600 as of 2/20 close »

S&P MidCap 400…

SFLY

Shutterfly

$48.06

0.66 (1.39%)

VASC

Vascular Solutions

TFX

Teleflex

$179.91

1.86 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NKTR

Nektar

$13.10

0.12 (0.92%)

, BMY

Bristol-Myers

$54.59

0.31 (0.57%)

14:48
02/20/17
02/20
14:48
02/20/17
14:48
Hot Stocks
Nektar reports Phase 1 data on NKTR-214 in kidney cancer »

Nektar Therapeutics…

NKTR

Nektar

$13.10

0.12 (0.92%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

XNCR

Xencor

$24.28

0.5 (2.10%)

14:38
02/20/17
02/20
14:38
02/20/17
14:38
Hot Stocks
Xencor announces data presentation on XmAb5871 »

Xencor announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RHHBY

Roche

$30.53

0.02 (0.07%)

14:35
02/20/17
02/20
14:35
02/20/17
14:35
Hot Stocks
Genentech reports Phase 2 data on Tecentriq combo in kidney cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 09

    Mar

  • 26

    Jun

RVSB

Riverview Bancorp

$7.50

-0.11 (-1.45%)

14:30
02/20/17
02/20
14:30
02/20/17
14:30
Hot Stocks
Breaking Hot Stocks news story on Riverview Bancorp »

Riverview Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.24

0.09 (1.75%)

14:27
02/20/17
02/20
14:27
02/20/17
14:27
Hot Stocks
Ocwen reaches settlement, termination of California consent order »

Ocwen Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SYF

Synchrony

$36.68

-0.17 (-0.46%)

14:07
02/20/17
02/20
14:07
02/20/17
14:07
Periodicals
Synchrony likely to see more gains, Barron's says »

Synchrony "still has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$160.25

-3.52 (-2.15%)

, CI

Cigna

$143.56

-1.77 (-1.22%)

14:05
02/20/17
02/20
14:05
02/20/17
14:05
Periodicals
Merger collapse could get Anthem back on track, Barron's says »

The likely collapse of…

ANTM

Anthem

$160.25

-3.52 (-2.15%)

CI

Cigna

$143.56

-1.77 (-1.22%)

ESRX

Express Scripts

$69.97

0.74 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

13:50
02/20/17
02/20
13:50
02/20/17
13:50
Periodicals
Restaurant Brands in advanced talks to buy Popeyes, Bloomberg says »

A deal could be announced…

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

AAPL

Apple

$135.72

0.375 (0.28%)

, AMAT

Applied Materials

$35.67

0.49 (1.39%)

13:48
02/20/17
02/20
13:48
02/20/17
13:48
Periodicals
Smartphone design trends could benefit Applied Materials, others, Barron's says »

As Apple (AAPL) and other…

AAPL

Apple

$135.72

0.375 (0.28%)

AMAT

Applied Materials

$35.67

0.49 (1.39%)

OLED

Universal Display

$72.15

0.85 (1.19%)

GLW

Corning

$27.65

-0.06 (-0.22%)

SSNLF

Samsung

LPL

LG Display

$12.39

0.07 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 13

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

  • 01

    Apr

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

, TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

13:32
02/20/17
02/20
13:32
02/20/17
13:32
Periodicals
Toshiba could have 50% upside, Barron's says »

Toshiba shares are…

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIN

DineEquity

$60.14

-6.41 (-9.63%)

13:27
02/20/17
02/20
13:27
02/20/17
13:27
Periodicals
DineEquity remains challenged, Barron's says »

"Problems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HD

Home Depot

$143.00

1.46 (1.03%)

13:09
02/20/17
02/20
13:09
02/20/17
13:09
Periodicals
Home Depot looks healthy into earnings report, Barron's says »

Home Depot remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

ADNT

Adient

$64.01

-0.69 (-1.07%)

, JCI

Johnson Controls

$41.91

0.23 (0.55%)

12:58
02/20/17
02/20
12:58
02/20/17
12:58
Periodicals
Adient could offer 35% upside, Barron's says »

Shares of Adient (ADNT)…

ADNT

Adient

$64.01

-0.69 (-1.07%)

JCI

Johnson Controls

$41.91

0.23 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$51.75

0.45 (0.88%)

12:47
02/20/17
02/20
12:47
02/20/17
12:47
Periodicals
Steer clear of Hess Corp, Barron's says »

Hess Corp shares are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

GM

General Motors

$37.22

0.19 (0.51%)

12:33
02/20/17
02/20
12:33
02/20/17
12:33
Periodicals
General Motors stock could reach $50 in a year, Barron's says »

Shares of General Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

11:43
02/20/17
02/20
11:43
02/20/17
11:43
Conference/Events
DA Davidson E&C and industrials analysts hold analyst/industry conference call »

E&C, Materials &…

11:38
02/20/17
02/20
11:38
02/20/17
11:38
Conference/Events
DA Davidson technology/software analysts hold analyst/industry conference call »

Technology Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.